Abstract
Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e510-e514 |
| Journal | The Lancet Oncology |
| Volume | 17 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials : a start in setting international standards. / Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.
In: The Lancet Oncology, Vol. 17, No. 11, 01.11.2016, p. e510-e514.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials
T2 - a start in setting international standards
AU - Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium
AU - Bottomley, Andrew
AU - Pe, Madeline
AU - Sloan, Jeff A
AU - Basch, Ethan
AU - Bonnetain, Franck
AU - Calvert, Melanie
AU - Campbell, Alicyn
AU - Cleeland, Charles
AU - Cocks, Kim
AU - Collette, Laurence
AU - Dueck, Amylou
AU - Devlin, Nancy
AU - Flechtner, Hans Henning
AU - Gotay, Carolyn
AU - Greimel, Eva
AU - Griebsch, Ingolf
AU - Groenvold, Mogens
AU - Hamel, Jean Francois
AU - King, Madeleine
AU - Kluetz, Paul G.
AU - Koller, Michael
AU - Malone, Daniel C.
AU - Martinelli, Francesca
AU - Mitchell, Sandra A.
AU - Moinpour, Carol M.
AU - Musoro, Jammbe
AU - O'Connor, Daniel
AU - Oliver, Kathy
AU - Piault-Louis, Elisabeth
AU - Piccart, Martine
AU - Pimentel, Francisco L.
AU - Quinten, Chantal
AU - Reijneveld, Jaap C.
AU - Schürmann, Christoph
AU - Smith, Ashley Wilder
AU - Soltys, Katherine M.
AU - Taphoorn, Martin J B
AU - Velikova, Galina
AU - Coens, Corneel
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
AB - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
UR - http://www.scopus.com/inward/record.url?scp=84995577351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995577351&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(16)30510-1
DO - 10.1016/S1470-2045(16)30510-1
M3 - Review article
C2 - 27769798
AN - SCOPUS:84995577351
VL - 17
SP - e510-e514
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 11
ER -